MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.320
-0.380
-10.27%
Closed 16:00 07/01 EDT
OPEN
3.705
PREV CLOSE
3.700
HIGH
3.750
LOW
3.270
VOLUME
36.46K
TURNOVER
86.79K
52 WEEK HIGH
20.96
52 WEEK LOW
2.530
MARKET CAP
37.86M
P/E (TTM)
-0.1507
1D
5D
1M
3M
1Y
5Y
Chemomab rises on patent win covering lead asset
Chemomab Therapeutics (NASDAQ:CMMB), a clinical-stage biotech focused on inflammation and fibrosis added ~7% in the pre-market Tuesday after the company announced that the U.S. regulators issued a new patent covering its lead
Seekingalpha · 3d ago
BRIEF-Chemomab Awarded New U.S. Patent For Cm-101, Its First-In-Class Ccl24 Neutralizing Antibody
BRIEF-Chemomab Awarded New U.S. Patent For Cm-101, Its First-In-Class Ccl24 Neutralizing Antibody
Reuters · 3d ago
Chemomab Therapeutics Secures US Patent for Liver Disease Therapy
MT Newswires · 3d ago
BRIEF-Chemomab Presents Data Further Supporting The Mechanism Of Action And Potential Efficacy Of CM-101 In Primary Sclerosing Cholangitis
BRIEF-Chemomab Presents Data Further Supporting The Mechanism Of Action And Potential Efficacy Of CM-101 In Primary Sclerosing Cholangitis
Reuters · 4d ago
Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported on two recent pres...
PR Newswire · 4d ago
BRIEF-Chemomab Therapeutics Appoints Jill M. Quigley, Jd, To Its Board Of Directors
BRIEF-Chemomab Therapeutics Appoints Jill M. Quigley, Jd, To Its Board Of Directors
Reuters · 06/21 13:24
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Jill M. Quig...
PR Newswire · 06/21 11:00
Chemomab Therapeutics to Present at June Investor and Scientific Conferences
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that the company ...
PR Newswire · 06/09 13:00
More
No Data
Learn about the latest financial forecast of CMMB. Analyze the recent business situations of Chemomab Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CMMB stock price target is 22.00 with a high estimate of 25.00 and a low estimate of 20.00.
High25.00
Average22.00
Low20.00
Current 3.320
EPS
Actual
Estimate
-0.35-0.26-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 21
Institutional Holdings: 3.61M
% Owned: 31.69%
Shares Outstanding: 11.40M
TypeInstitutionsShares
Increased
4
20.96K
New
7
329.25K
Decreased
3
270.00K
Sold Out
5
60.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Squinto
Chief Executive Officer/Chief Scientific Officer/Director
Adi Mor
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Donald Marvin
Other
Arnon Aharon
Other
David Weiner
Independent Director
Neil Cohen
Independent Director
Nissim Darvish
Independent Director
Joel Maryles
Independent Director
Alan Moses
Independent Director
Claude Nicaise
No Data
No Data
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers kinds of Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ:CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.